Indikation (Clinical Trials):
Carcinoma, Carcinoma, Squamous Cell, Squamous Cell Carcinoma of Head and Neck
Geschlecht:
Alle
Altersgruppe:
Erwachsene (18+)
Phase:
-
Sponsor:
Technische Universität Dresden
Collaborator:
German Cancer Research Center, National Center for Tumor Diseases (NCT) Dresden, National Center for Tumor Diseases, Heidelberg, Radiation Oncology Working Group of the German Cancer Society,
Studienleiter
Mechthild Krause, Prof. Study Chair University of Technology, University Hospital Carl Gustav Carus, Department of Radiation Therapy and Radiation Oncology, German Consortium for Translational Cancer Research (DKTK)
1. rate of locoregional recurrences (Time Frame - 24 months after end of treatment): measured from the last day of treatment
Secondary outcome:
1. overall survival (Time Frame - 60 months and 5 years after end of treatment): measured from the last day of treatment
2. acute toxicity (Time Frame - 3 months after end of treatment): The occurrence of acute side effects (up to 90 days after start of treatment) will be recorded and documented based on CTCAE 4.0.
3. late toxicity (Time Frame - 24 months after end of treatment): The occurrence of late side effects will be recorded and documented based on CTCAE 4.0 after every follow-up visit.
4. quality of life of cancer patients (Time Frame - 24 months after end of treatment): The assessment of quality of life (QoL) is carried out using the EORTC quality of life questionnaire (QLQ) C30. Quality of life will be documented immediately before the start of therapy, after completion of postoperative radiotherapy and at every follow-up visit. QOL will be measured as change from baseline over time.
5. quality of life - disease specific (Time Frame - 24 months after end of treatment): The assessment of quality of life (QOL) is carried out using the EORTC quality of life questionnaire (QLQ) disease-specific module for head and neck cancer H&N35. Quality of life will be documented immediately before the start of therapy, after completion of postoperative radiotherapy and at every follow-up visit. QOL will be measured as change from baseline over time.
6. rate of locoregional recurrences (Time Frame - 5 years after end of treatment): measured from the last day of treatment